Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 5,388 matching trials from the live ClinicalTrials.gov search.
Filters: Tucson, Arizona Clear all
Completed Phase 2 Interventional Results available

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02823574
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Nivolumab, Ipilimumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
28
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00002597
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, Zoladex, Lupron, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
2,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2018
U.S. locations
222
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 25, 2026, 5:28 PM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation of the Default Mode Network to Improve Sleep

NCT04953559
View directory record Official record
Conditions
Insomnia, Primary
Interventions
Active cTBS, Sham cTBS
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00424528
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions
Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
45 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
28
States / cities
Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers

NCT03402230
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma, Tobacco-Related Carcinoma
Interventions
Broccoli Sprout/Broccoli Seed Extract Supplement, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 4 Interventional

Phase 4 IOP Signals Associated With ILUVIEN®

NCT02424019
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
ILUVIEN 0.19 MG
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
Not listed
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

NCT00111007
View directory record Official record
Conditions
Melanoma
Interventions
Sorafenib (Nexavar, BAY43-9006), Carboplatin/Paclitaxel, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

NCT00499707
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone maleate/metformin hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL

NCT00732498
View directory record Official record
Conditions
Lymphoma
Interventions
Methylprednisolone, Etoposide, Cytarabine, Cisplatin, Rituximab, In-Zevalin, Y-Zevalin
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)

NCT00675584
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, Placebo Budesonide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 53 Months
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 25, 2026, 5:28 PM EDT
Terminated Phase 2 Interventional Results available

Supplemental Parenteral Nutrition in Pediatric Respiratory Failure

NCT01937884
View directory record Official record
Conditions
Acute Respiratory Failure With Hypoxia, Malnutrition
Interventions
Parenteral Nutrition
Drug
Lead sponsor
University of Arizona
Other
Eligibility
1 Month to 16 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

NCT00185133
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
139
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

Virtual Reality-based Exercise in Older Adults

NCT02043834
View directory record Official record
Conditions
Distorted; Balance, Motor Deficit
Interventions
Balance Training
Other
Lead sponsor
University of Arizona
Other
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

NCT00095199
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cetuximab, Docetaxel
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional

SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme

NCT00003293
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
leflunomide, procarbazine hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Not applicable Interventional

The PROTEMBO Trial

NCT05873816
View directory record Official record
Conditions
Severe Aortic Valve Stenosis
Interventions
ProtEmbo - Cerebral Embolic Protection, Sentinel - Cerebral Embolic Protection
Device
Lead sponsor
Protembis GmbH
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

NCT03805100
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Biological
Lead sponsor
Xbrane Biopharma AB
Industry
Eligibility
50 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 4 Interventional

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

NCT00246909
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Pantoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Alabaster, Alabama • Huntsville, Alabama • Mesa, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 1Phase 2 Interventional

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

NCT00257465
View directory record Official record
Conditions
Melanoma
Interventions
Autologous, DNP-modified vaccine (M-Vax), Autologous, DNP-Modified Melanoma Vaccine, Autologous, DNP-Modified Vaccine
Biological
Lead sponsor
AVAX Technologies
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Tucson, Arizona • San Diego, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

NCT01240863
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
73
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)

NCT00032487
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin, Glimepiride, Rosiglitazone, Metformin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
1,791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 25, 2026, 5:28 PM EDT
Completed Phase 3 Interventional Results available

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Oct 25, 2026, 5:28 PM EDT
No Longer Available No phase listed Expanded access

Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma

NCT02715843
View directory record Official record
Conditions
Non-Hodgkin's B-cell Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Tucson, Arizona • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 25, 2026, 5:28 PM EDT